Free Trial
NASDAQ:JAGX

Jaguar Health (JAGX) Stock Price, News & Analysis

Jaguar Health logo
$1.05
-0.01 (-0.94%)
(As of 10/31/2024 ET)

About Jaguar Health Stock (NASDAQ:JAGX)

Key Stats

Today's Range
$1.03
$1.07
50-Day Range
$1.05
$1.35
52-Week Range
$0.95
$30.86
Volume
241,391 shs
Average Volume
763,605 shs
Market Capitalization
$5.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Jaguar Health Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
19th Percentile Overall Score

JAGX MarketRank™: 

Jaguar Health scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Jaguar Health are expected to decrease in the coming year, from ($0.78) to ($2.61) per share.

  • Price to Book Value per Share Ratio

    Jaguar Health has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Jaguar Health's valuation and earnings.
  • Percentage of Shares Shorted

    1.81% of the float of Jaguar Health has been sold short.
  • Short Interest Ratio / Days to Cover

    Jaguar Health has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Jaguar Health has recently decreased by 66.25%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Jaguar Health does not currently pay a dividend.

  • Dividend Growth

    Jaguar Health does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.81% of the float of Jaguar Health has been sold short.
  • Short Interest Ratio / Days to Cover

    Jaguar Health has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Jaguar Health has recently decreased by 66.25%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Jaguar Health has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Jaguar Health this week, compared to 1 article on an average week.
  • Search Interest

    Only 2 people have searched for JAGX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Jaguar Health insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.01% of the stock of Jaguar Health is held by insiders.

  • Percentage Held by Institutions

    Only 12.04% of the stock of Jaguar Health is held by institutions.

  • Read more about Jaguar Health's insider trading history.
Receive JAGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jaguar Health and its competitors with MarketBeat's FREE daily newsletter.

JAGX Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
See More Headlines

JAGX Stock Analysis - Frequently Asked Questions

Jaguar Health's stock was trading at $9.0840 on January 1st, 2024. Since then, JAGX stock has decreased by 88.4% and is now trading at $1.05.
View the best growth stocks for 2024 here
.

Jaguar Health, Inc. (NASDAQ:JAGX) posted its quarterly earnings data on Tuesday, August, 13th. The biotechnology company reported ($4.04) EPS for the quarter, missing the consensus estimate of ($1.20) by $2.84. The biotechnology company earned $2.72 million during the quarter. Jaguar Health had a negative net margin of 350.18% and a negative trailing twelve-month return on equity of 412.63%.

Shares of Jaguar Health reverse split on Thursday, May 23rd 2024. The 1-60 reverse split was announced on Thursday, May 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Jaguar Health (JAGX) raised $22 million in an initial public offering (IPO) on Wednesday, May 13th 2015. The company issued 3,200,000 shares at $7.00 per share. Aegis Capital Corp acted as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.

Shares of JAGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Jaguar Health investors own include Block (SQ), CrowdStrike (CRWD), Palantir Technologies (PLTR), NVIDIA (NVDA), Meta Platforms (META), Digital Turbine (APPS) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
8/13/2024
Today
10/31/2024
Next Earnings (Estimated)
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:JAGX
Fax
N/A
Employees
50
Year Founded
N/A

Profitability

Net Income
$-41,300,000.00
Net Margins
-350.18%
Pretax Margin
-355.51%

Debt

Sales & Book Value

Annual Sales
$10.19 million
Book Value
$4.02 per share

Miscellaneous

Free Float
9,240,000
Market Cap
$5.15 million
Optionable
No Data
Beta
0.83

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:JAGX) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners